{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:08:50Z","timestamp":1788908930251,"version":"build-2803163510"},"reference-count":140,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Saudi Pharm. J."],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s44446-026-00107-w","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:43:01Z","timestamp":1786462981000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gut microbiota modulation of systemic immunity and cancer immunotherapy: mechanisms, evidence, and therapeutic implications"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6878-257X","authenticated-orcid":false,"given":"Bader S.","family":"Alotaibi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"107_CR1","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1038\/s41591-021-01406-6","volume":"27","author":"MC Andrews","year":"2021","unstructured":"Andrews MC, Duong CPM, Gopalakrishnan V et al (2021) Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med 27:1432\u20131441. https:\/\/doi.org\/10.1038\/s41591-021-01406-6","journal-title":"Nat Med"},{"key":"107_CR2","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1146\/annurev-immunol-093019-112348","volume":"39","author":"E Ansaldo","year":"2021","unstructured":"Ansaldo E, Farley TK, Belkaid Y (2021) Control of immunity by the microbiota. Annu Rev Immunol 39:449\u2013479. https:\/\/doi.org\/10.1146\/annurev-immunol-093019-112348","journal-title":"Annu Rev Immunol"},{"key":"107_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","volume":"17","author":"J Aron-Wisnewsky","year":"2020","unstructured":"Aron-Wisnewsky J, Vigliotti C, Witjes J et al (2020) Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol 17:279\u2013297. https:\/\/doi.org\/10.1038\/s41575-020-0269-9","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"107_CR4","doi-asserted-by":"publisher","first-page":"5707150","DOI":"10.1155\/2019\/5707150","volume":"2019","author":"Y Becerril-Alarc\u00f3n","year":"2019","unstructured":"Becerril-Alarc\u00f3n Y, Campos-G\u00f3mez S, Valdez-Andrade JJ et al (2019) Inulin supplementation reduces systolic blood pressure in women with breast cancer undergoing neoadjuvant chemotherapy. Cardiovasc Ther 2019:5707150. https:\/\/doi.org\/10.1155\/2019\/5707150","journal-title":"Cardiovasc Ther"},{"key":"107_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101234","author":"PP Bloom","year":"2025","unstructured":"Bloom PP, Chung RT (2025) The future of clinical trials of gut microbiome therapeutics in cirrhosis. JHEP Rep. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101234","journal-title":"JHEP Rep"},{"key":"107_CR6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12967-020-02231-0","volume":"18","author":"A Botticelli","year":"2020","unstructured":"Botticelli A, Vernocchi P, Marini F et al (2020) Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment. J Transl Med 18:49. https:\/\/doi.org\/10.1186\/s12967-020-02231-0","journal-title":"J Transl Med"},{"key":"107_CR7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41575-019-0261-4","volume":"17","author":"JF Burgue\u00f1o","year":"2020","unstructured":"Burgue\u00f1o JF, Abreu MT (2020) Epithelial Toll-like receptors and their role in gut homeostasis and disease. Nat Rev Gastroenterol Hepatol 17:263\u2013278. https:\/\/doi.org\/10.1038\/s41575-019-0261-4","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"107_CR8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.chom.2022.02.004","volume":"30","author":"J Cai","year":"2022","unstructured":"Cai J, Sun L, Gonzalez FJ (2022) Gut microbiota-derived bile acids in intestinal immunity, inflammation, and tumorigenesis. Cell Host Microbe 30:289\u2013300. https:\/\/doi.org\/10.1016\/j.chom.2022.02.004","journal-title":"Cell Host Microbe"},{"key":"107_CR9","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41591-020-01224-2","volume":"27","author":"T Cascone","year":"2021","unstructured":"Cascone T, William WN, Weissferdt A et al (2021) Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med 27:504\u2013514. https:\/\/doi.org\/10.1038\/s41591-020-01224-2","journal-title":"Nat Med"},{"key":"107_CR10","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","volume":"28","author":"N Chaput","year":"2017","unstructured":"Chaput N, Lepage P, Coutzac C et al (2017) Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol 28:1368\u20131379. https:\/\/doi.org\/10.1093\/annonc\/mdx108","journal-title":"Ann Oncol"},{"key":"107_CR11","doi-asserted-by":"publisher","unstructured":"Cheng, P., P. Shen, Y. Shan, et al., 2021. Gut microbiota-mediated modulation of cancer progression and therapy efficacy. frontiers in cell and developmental biology. volume 9 - 2021, https:\/\/doi.org\/10.3389\/fcell.2021.626045","DOI":"10.3389\/fcell.2021.626045"},{"key":"107_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26010206","volume":"26","author":"H Choudhry","year":"2021","unstructured":"Choudhry H (2021) The microbiome and its implications in cancer immunotherapy. Molecules 26:206","journal-title":"Molecules"},{"key":"107_CR13","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1053\/j.gastro.2022.10.018","volume":"164","author":"D Chrysostomou","year":"2023","unstructured":"Chrysostomou D, Roberts LA, Marchesi JR et al (2023) Gut microbiota modulation of efficacy and toxicity of cancer chemotherapy and immunotherapy. Gastroenterology 164:198\u2013213. https:\/\/doi.org\/10.1053\/j.gastro.2022.10.018","journal-title":"Gastroenterology"},{"key":"107_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011281","author":"MA Clavijo-Salomon","year":"2025","unstructured":"Clavijo-Salomon MA, Trinchieri G (2025) Unlocking the power of the microbiome for successful cancer immunotherapy. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2024-011281","journal-title":"J Immunother Cancer"},{"key":"107_CR15","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.cell.2019.07.049","volume":"178","author":"N Collins","year":"2019","unstructured":"Collins N, Han SJ, Enamorado M et al (2019) The bone marrow protects and optimizes immunological memory during dietary restriction. Cell 178:1088-1101.e1015. https:\/\/doi.org\/10.1016\/j.cell.2019.07.049","journal-title":"Cell"},{"key":"107_CR16","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1177\/0148607115584387","volume":"40","author":"MLD Consoli","year":"2016","unstructured":"Consoli MLD, da Silva RS, Nicoli JR et al (2016) Randomized clinical trial: impact of oral administration of saccharomyces boulardii on gene expression of intestinal cytokines in patients undergoing colon resection. J Parenter Enter Nutr 40:1114\u20131121. https:\/\/doi.org\/10.1177\/0148607115584387","journal-title":"J Parenter Enter Nutr"},{"key":"107_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9030618","author":"RA Corb Aron","year":"2021","unstructured":"Corb Aron RA, Abid A, Vesa CM et al (2021) Recognizing the benefits of pre-\/probiotics in metabolic syndrome and type 2 diabetes mellitus considering the influence of Akkermansia muciniphila as a key gut bacterium. Microorganisms. https:\/\/doi.org\/10.3390\/microorganisms9030618","journal-title":"Microorganisms"},{"key":"107_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16079-x","volume":"11","author":"C Coutzac","year":"2020","unstructured":"Coutzac C, Jouniaux J-M, Paci A et al (2020a) Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. Nat Commun 11:2168. https:\/\/doi.org\/10.1038\/s41467-020-16079-x","journal-title":"Nat Commun"},{"key":"107_CR19","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1038\/s41467-020-16079-x","volume":"11","author":"C Coutzac","year":"2020","unstructured":"Coutzac C, Jouniaux JM, Paci A et al (2020b) Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. Nat Commun 11:2168. https:\/\/doi.org\/10.1038\/s41467-020-16079-x","journal-title":"Nat Commun"},{"key":"107_CR20","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/eji.201948354","volume":"50","author":"G D'Alessandro","year":"2020","unstructured":"D\u2019Alessandro G, Antonangeli F, Marrocco F et al (2020) Gut microbiota alterations affect glioma growth and innate immune cells involved in tumor immunosurveillance in mice. Eur J Immunol 50:705\u2013711. https:\/\/doi.org\/10.1002\/eji.201948354","journal-title":"Eur J Immunol"},{"key":"107_CR21","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/S1470-2045(18)30919-7","volume":"20","author":"M Das","year":"2019","unstructured":"Das M (2019) Probiotics for chemoradiotherapy-induced oral mucositis. Lancet Oncol 20:e14. https:\/\/doi.org\/10.1016\/S1470-2045(18)30919-7","journal-title":"Lancet Oncol"},{"key":"107_CR22","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","volume":"371","author":"D Davar","year":"2021","unstructured":"Davar D, Dzutsev AK, McCulloch JA et al (2021) Fecal microbiota transplant overcomes resistance to anti\u2013PD-1 therapy in melanoma patients. Science 371:595\u2013602. https:\/\/doi.org\/10.1126\/science.abf3363","journal-title":"Science"},{"key":"107_CR23","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1016\/j.ccell.2024.10.007","volume":"42","author":"D Davar","year":"2024","unstructured":"Davar D, Morrison RM, Dzutsev AK et al (2024) Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial. Cancer Cell 42:1898-1918.e1812. https:\/\/doi.org\/10.1016\/j.ccell.2024.10.007","journal-title":"Cancer Cell"},{"key":"107_CR24","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdy103","volume":"29","author":"L Derosa","year":"2018","unstructured":"Derosa L, Hellmann MD, Spaziano M et al (2018) Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol 29:1437\u20131444. https:\/\/doi.org\/10.1093\/annonc\/mdy103","journal-title":"Ann Oncol"},{"key":"107_CR25","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1016\/j.cell.2024.05.029","volume":"187","author":"L Derosa","year":"2024","unstructured":"Derosa L, Iebba V, Silva CAC et al (2024) Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome. Cell 187:3373-3389.e3316. https:\/\/doi.org\/10.1016\/j.cell.2024.05.029","journal-title":"Cell"},{"key":"107_CR26","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41591-021-01655-5","volume":"28","author":"L Derosa","year":"2022","unstructured":"Derosa L, Routy B, Thomas AM et al (2022) Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat Med 28:315\u2013324. https:\/\/doi.org\/10.1038\/s41591-021-01655-5","journal-title":"Nat Med"},{"key":"107_CR27","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.cell.2016.10.043","volume":"167","author":"MS Desai","year":"2016","unstructured":"Desai MS, Seekatz AM, Koropatkin NM et al (2016) A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility. Cell 167:1339-1353.e1321. https:\/\/doi.org\/10.1016\/j.cell.2016.10.043","journal-title":"Cell"},{"key":"107_CR28","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1158\/0008-5472.Can-20-1659","volume":"81","author":"M Di Modica","year":"2021","unstructured":"Di Modica M, Gargari G, Regondi V et al (2021) Gut microbiota condition the therapeutic efficacy of trastuzumab in HER2-positive breast cancer. Can Res 81:2195\u20132206. https:\/\/doi.org\/10.1158\/0008-5472.Can-20-1659","journal-title":"Can Res"},{"key":"107_CR29","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41591-022-01694-6","volume":"28","author":"N Dizman","year":"2022","unstructured":"Dizman N, Meza L, Bergerot P et al (2022) Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat Med 28:704\u2013712. https:\/\/doi.org\/10.1038\/s41591-022-01694-6","journal-title":"Nat Med"},{"key":"107_CR30","doi-asserted-by":"publisher","first-page":"8434","DOI":"10.3390\/curroncol30090614","volume":"30","author":"E Domzaridou","year":"2023","unstructured":"Domzaridou E, Van Staa T, Renehan AG et al (2023) The impact of oral antibiotics prior to cancer diagnosis on overall patient survival: findings from an english population-based cohort study. Curr Oncol 30:8434\u20138443. https:\/\/doi.org\/10.3390\/curroncol30090614","journal-title":"Curr Oncol"},{"key":"107_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032769","volume":"24","author":"D Dora","year":"2023","unstructured":"Dora D, Bokhari SMZ, Aloss K et al (2023) Implication of the gut microbiome and microbial-derived metabolites in immune-related adverse events: emergence of novel biomarkers for cancer immunotherapy. Int J Mol Sci 24:2769","journal-title":"Int J Mol Sci"},{"key":"107_CR32","doi-asserted-by":"publisher","first-page":"10391","DOI":"10.1038\/ncomms10391","volume":"7","author":"K Dubin","year":"2016","unstructured":"Dubin K, Callahan MK, Ren B et al (2016) Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun 7:10391. https:\/\/doi.org\/10.1038\/ncomms10391","journal-title":"Nat Commun"},{"key":"107_CR33","doi-asserted-by":"crossref","unstructured":"Engevik MA, Luk B, Chang-Graham AL, Hall A, Herrmann B, Ruan W, Endres BT, Shi Z, Garey KW, Hyser JM, Versalovic J. Bifidobacterium dentium fortifies the intestinal mucus layer via autophagy and calcium signaling pathways. MBio. 2019 Jun 25;10(3):10-128. 10.1128\/mbio.01087-01019, 10.1128\/mbio.01087-19","DOI":"10.1128\/mBio.01087-19"},{"key":"107_CR34","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1159\/000508328","volume":"102","author":"X Fan","year":"2020","unstructured":"Fan X, Jin Y, Chen G et al (2020) Gut microbiota dysbiosis drives the development of colorectal cancer. Digestion 102:508\u2013515. https:\/\/doi.org\/10.1159\/000508328","journal-title":"Digestion"},{"issue":"2","key":"107_CR35","doi-asserted-by":"publisher","first-page":"e145207","DOI":"10.1172\/jci.insight.145207","volume":"6","author":"G Ferrere","year":"2021","unstructured":"Ferrere G, Alou MT, Liu P, Goubet AG, Fidelle M, Kepp O, Durand S, Iebba V, Fluckiger A, Daill\u00e8re R, Thelemaque C (2021) Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade. JCI Insight 6(2):e145207. https:\/\/doi.org\/10.1172\/jci.insight.145207","journal-title":"JCI Insight"},{"key":"107_CR36","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1126\/science.aax0701","volume":"369","author":"A Fluckiger","year":"2020","unstructured":"Fluckiger A, Daill\u00e8re R, Sassi M et al (2020) Cross-reactivity between tumor MHC class I\u2013restricted antigens and an enterococcal bacteriophage. Science 369:936\u2013942. https:\/\/doi.org\/10.1126\/science.aax0701","journal-title":"Science"},{"key":"107_CR37","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1136\/gutjnl-2023-329543","volume":"72","author":"W Fong","year":"2023","unstructured":"Fong W, Li Q, Ji F et al (2023) Lactobacillus gallinarum-derived metabolites boost anti-PD1 efficacy in colorectal cancer by inhibiting regulatory T cells through modulating IDO1\/Kyn\/AHR axis. Gut 72:2272\u20132285. https:\/\/doi.org\/10.1136\/gutjnl-2023-329543","journal-title":"Gut"},{"key":"107_CR38","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1080\/19490976.2018.1465157","volume":"9","author":"AC Gomes","year":"2018","unstructured":"Gomes AC, Hoffmann C, Mota JF (2018) The human gut microbiota: Metabolism and perspective in obesity. Gut Microbes 9:308\u2013325. https:\/\/doi.org\/10.1080\/19490976.2018.1465157","journal-title":"Gut Microbes"},{"key":"107_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158343","volume":"23","author":"X Guo","year":"2022","unstructured":"Guo X, Okpara ES, Hu W et al (2022) Interactive relationships between intestinal flora and bile acids. Int J Mol Sci 23:8343","journal-title":"Int J Mol Sci"},{"key":"107_CR40","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.cmet.2021.03.002","volume":"33","author":"Y He","year":"2021","unstructured":"He Y, Fu L, Li Y et al (2021) Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8+ T\u00a0cell immunity. Cell Metab 33:988-1000.e1007. https:\/\/doi.org\/10.1016\/j.cmet.2021.03.002","journal-title":"Cell Metab"},{"key":"107_CR41","doi-asserted-by":"publisher","first-page":"e000145","DOI":"10.1136\/bmjgast-2017-000145","volume":"4","author":"AA Hibberd","year":"2017","unstructured":"Hibberd AA, Lyra A, Ouwehand AC et al (2017) Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention. BMJ Open Gastroenterol 4:e000145. https:\/\/doi.org\/10.1136\/bmjgast-2017-000145","journal-title":"BMJ Open Gastroenterol"},{"issue":"10","key":"107_CR42","doi-asserted-by":"publisher","first-page":"5740","DOI":"10.3390\/ijms23105740","volume":"23","author":"M Hu","year":"2022","unstructured":"Hu M, AlashkarAlhamwe B, Santner-Nanan B, Miethe S, Harb H, Renz H, Potaczek DP, Nanan RK (2022) Short-chain fatty acids augment differentiation and function of human induced regulatory T cells. Int J Molecul Sci 23(10):5740. https:\/\/doi.org\/10.3390\/ijms23105740","journal-title":"Int J Molecul Sci"},{"key":"107_CR43","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1136\/gutjnl-2020-321031","volume":"71","author":"J Huang","year":"2022","unstructured":"Huang J, Liu D, Wang Y et al (2022a) Ginseng polysaccharides alter the gut microbiota and kynurenine\/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1\/programmed cell death ligand 1 (anti-PD-1\/PD-L1) immunotherapy. Gut 71:734\u2013745. https:\/\/doi.org\/10.1136\/gutjnl-2020-321031","journal-title":"Gut"},{"issue":"13","key":"107_CR44","doi-asserted-by":"publisher","first-page":"874922","DOI":"10.3389\/fimmu.2022.874922","volume":"15","author":"J Huang","year":"2022","unstructured":"Huang J, Zheng X, Kang W, Hao H, Mao Y, Zhang H, Chen Y, Tan Y, He Y, Zhao W, Yin Y (2022) Metagenomic and metabolomic analyses reveal synergistic effects of fecal microbiota transplantation and anti-PD-1 therapy on treating colorectal cancer. Front Immunol 15(13):874922. https:\/\/doi.org\/10.3389\/fimmu.2022.874922","journal-title":"Front Immunol"},{"key":"107_CR45","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1016\/j.chom.2023.10.005","volume":"31","author":"X Huang","year":"2023","unstructured":"Huang X, Hu M, Sun T et al (2023) Multi-kingdom gut microbiota analyses define bacterial-fungal interplay and microbial markers of pan-cancer immunotherapy across cohorts. Cell Host Microbe 31:1930-1943.e1934. https:\/\/doi.org\/10.1016\/j.chom.2023.10.005","journal-title":"Cell Host Microbe"},{"key":"107_CR46","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S1473-3099(15)00293-5","volume":"15","author":"P Hugon","year":"2015","unstructured":"Hugon P, Dufour J-C, Colson P et al (2015) A comprehensive repertoire of prokaryotic species identified in human beings. Lancet Infect Dis 15:1211\u20131219. https:\/\/doi.org\/10.1016\/S1473-3099(15)00293-5","journal-title":"Lancet Infect Dis"},{"key":"107_CR47","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1038\/s41591-022-01964-3","volume":"28","author":"G Ianiro","year":"2022","unstructured":"Ianiro G, Pun\u010doch\u00e1\u0159 M, Karcher N et al (2022) Variability of strain engraftment and predictability of microbiome composition after fecal microbiota transplantation across different diseases. Nat Med 28:1913\u20131923. https:\/\/doi.org\/10.1038\/s41591-022-01964-3","journal-title":"Nat Med"},{"key":"107_CR48","doi-asserted-by":"publisher","first-page":"16","DOI":"10.15430\/jcp.2022.27.1.16","volume":"27","author":"R Issrani","year":"2022","unstructured":"Issrani R, Reddy J, Dabah THE et al (2022) Role of oral microbiota in carcinogenesis: a short review. J Cancer Prev 27:16\u201321. https:\/\/doi.org\/10.15430\/jcp.2022.27.1.16","journal-title":"J Cancer Prev"},{"key":"107_CR49","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/cncr.31907","volume":"125","author":"C Jiang","year":"2019","unstructured":"Jiang C, Wang H, Xia C et al (2019) A randomized, double-blind, placebo-controlled trial of probiotics to reduce the severity of oral mucositis induced by chemoradiotherapy for patients with nasopharyngeal carcinoma. Cancer 125:1081\u20131090. https:\/\/doi.org\/10.1002\/cncr.31907","journal-title":"Cancer"},{"key":"107_CR50","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/j.jtho.2019.04.007","volume":"14","author":"Y Jin","year":"2019","unstructured":"Jin Y, Dong H, Xia L et al (2019) The diversity of gut microbiome is associated with favorable responses to anti\u2013programmed death 1 immunotherapy in Chinese patients with NSCLC. J Thorac Oncol 14:1378\u20131389. https:\/\/doi.org\/10.1016\/j.jtho.2019.04.007","journal-title":"J Thorac Oncol"},{"issue":"14","key":"107_CR51","doi-asserted-by":"publisher","first-page":"1195075","DOI":"10.3389\/fimmu.2023.1195075","volume":"26","author":"N Jing","year":"2023","unstructured":"Jing N, Wang L, Zhuang H, Jiang G, Liu Z (2023) Enhancing therapeutic effects of murine cancer vaccine by reshaping gut microbiota with Lactobacillus rhamnosus GG and jujube powder. Front Immunol 26(14):1195075. https:\/\/doi.org\/10.3389\/fimmu.2023.1195075","journal-title":"Front Immunol"},{"key":"107_CR52","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.chom.2015.10.007","volume":"18","author":"MEV Johansson","year":"2015","unstructured":"Johansson MEV, Jakobsson HE, Holm\u00e9n-Larsson J et al (2015) Normalization of host intestinal mucus layers requires long-term microbial colonization. Cell Host Microbe 18:582\u2013592. https:\/\/doi.org\/10.1016\/j.chom.2015.10.007","journal-title":"Cell Host Microbe"},{"key":"107_CR53","doi-asserted-by":"publisher","first-page":"e787","DOI":"10.1016\/S2666-5247(22)00185-9","volume":"3","author":"A Jordan","year":"2022","unstructured":"Jordan A, Carding SR, Hall LJ (2022) The early-life gut microbiome and vaccine efficacy. Lancet Microbe 3:e787\u2013e794. https:\/\/doi.org\/10.1016\/S2666-5247(22)00185-9","journal-title":"Lancet Microbe"},{"key":"107_CR54","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.it.2023.12.002","volume":"45","author":"CKI Jordan","year":"2024","unstructured":"Jordan CKI, Clarke TB (2024) How does the microbiota control systemic innate immunity? Trends Immunol 45:94\u2013102. https:\/\/doi.org\/10.1016\/j.it.2023.12.002","journal-title":"Trends Immunol"},{"key":"107_CR55","doi-asserted-by":"publisher","unstructured":"Kang X, Lau HC, Yu J. Modulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy. Cell Reports Medicine. 2024 Apr 16;5(4). https:\/\/doi.org\/10.1016\/j.xcrm.2024.101478","DOI":"10.1016\/j.xcrm.2024.101478"},{"key":"107_CR56","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1136\/gutjnl-2023-330291","volume":"72","author":"X Kang","year":"2023","unstructured":"Kang X, Liu C, Ding Y et al (2023) Roseburia intestinalis generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8+ T cells. Gut 72:2112\u20132122. https:\/\/doi.org\/10.1136\/gutjnl-2023-330291","journal-title":"Gut"},{"key":"107_CR57","doi-asserted-by":"publisher","first-page":"847","DOI":"10.21037\/tlcr.2019.10.23","volume":"8","author":"Y Katayama","year":"2019","unstructured":"Katayama Y, Yamada T, Shimamoto T et al (2019) The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer. Transl Lung Cancer Res 8:847\u2013853. https:\/\/doi.org\/10.21037\/tlcr.2019.10.23","journal-title":"Transl Lung Cancer Res"},{"key":"107_CR58","doi-asserted-by":"publisher","first-page":"863","DOI":"10.6004\/jnccn.2017.0127","volume":"15","author":"S Kato","year":"2017","unstructured":"Kato S, Subbiah V, Kurzrock R (2017) Counterpoint: successes in the pursuit of precision medicine: biomarkers take credit. J Natl Compr Canc Netw 15:863\u2013866. https:\/\/doi.org\/10.6004\/jnccn.2017.0127","journal-title":"J Natl Compr Canc Netw"},{"key":"107_CR59","doi-asserted-by":"publisher","first-page":"277","DOI":"10.4110\/in.2014.14.6.277","volume":"14","author":"CH Kim","year":"2014","unstructured":"Kim CH, Park J, Kim M (2014) Gut microbiota-derived short-chain fatty acids, T cells, and inflammation. Immune Netw 14:277\u2013288. https:\/\/doi.org\/10.4110\/in.2014.14.6.277","journal-title":"Immune Netw"},{"key":"107_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6267-z","volume":"19","author":"H Kim","year":"2019","unstructured":"Kim H, Lee JE, Hong SH et al (2019) The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study. BMC Cancer 19:1100. https:\/\/doi.org\/10.1186\/s12885-019-6267-z","journal-title":"BMC Cancer"},{"issue":"12","key":"107_CR61","doi-asserted-by":"publisher","first-page":"1004339","DOI":"10.3389\/fcimb.2022.1004339","volume":"13","author":"KS Kim","year":"2022","unstructured":"Kim KS (2022) Regulation of T cell repertoires by commensal microbiota. Front Cellul Infect Microbiol 13(12):1004339. https:\/\/doi.org\/10.3389\/fcimb.2022.1004339","journal-title":"Front Cellul Infect Microbiol"},{"key":"107_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15072101","author":"DE Kiousi","year":"2023","unstructured":"Kiousi DE, Kouroutzidou AZ, Neanidis K et al (2023) The role of the gut microbiome in cancer immunotherapy: current knowledge and future directions. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15072101","journal-title":"Cancers (Basel)"},{"key":"107_CR63","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.cell.2016.05.041","volume":"165","author":"A Koh","year":"2016","unstructured":"Koh A, De Vadder F, Kovatcheva-Datchary P et al (2016) From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell 165:1332\u20131345. https:\/\/doi.org\/10.1016\/j.cell.2016.05.041","journal-title":"Cell"},{"key":"107_CR64","doi-asserted-by":"publisher","DOI":"10.1136\/egastro-2023-100007","volume":"1","author":"HCH Lau","year":"2023","unstructured":"Lau HCH, Zhang X, Yu J (2023) Gut microbiota and immune alteration in cancer development: implication for immunotherapy. eGastroenterology 1:e100007. https:\/\/doi.org\/10.1136\/egastro-2023-100007","journal-title":"eGastroenterology"},{"key":"107_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-36926-8","volume":"9","author":"DL Laut\u00e9-Caly","year":"2019","unstructured":"Laut\u00e9-Caly DL, Raftis EJ, Cowie P et al (2019) The flagellin of candidate live biotherapeutic Enterococcus gallinarum MRx0518 is a potent immunostimulant. Sci Rep 9:801. https:\/\/doi.org\/10.1038\/s41598-018-36926-8","journal-title":"Sci Rep"},{"key":"107_CR66","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-019-0258-z","volume":"17","author":"A Lavelle","year":"2020","unstructured":"Lavelle A, Sokol H (2020) Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 17:223\u2013237. https:\/\/doi.org\/10.1038\/s41575-019-0258-z","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"107_CR67","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41564-020-00831-6","volume":"6","author":"S-H Lee","year":"2021","unstructured":"Lee S-H, Cho S-Y, Yoon Y et al (2021) Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice. Nat Microbiol 6:277\u2013288. https:\/\/doi.org\/10.1038\/s41564-020-00831-6","journal-title":"Nat Microbiol"},{"key":"107_CR68","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41522-025-00786-8","volume":"11","author":"W Lei","year":"2025","unstructured":"Lei W, Zhou K, Lei Y et al (2025) Gut microbiota shapes cancer immunotherapy responses. NPJ Biofilms Microbiomes 11:143. https:\/\/doi.org\/10.1038\/s41522-025-00786-8","journal-title":"NPJ Biofilms Microbiomes"},{"key":"107_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-021-01872-z","volume":"22","author":"N Li","year":"2021","unstructured":"Li N, Dai Z, Wang Z et al (2021) Gut microbiota dysbiosis contributes to the development of chronic obstructive pulmonary disease. Respir Res 22:274. https:\/\/doi.org\/10.1186\/s12931-021-01872-z","journal-title":"Respir Res"},{"key":"107_CR70","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1898832","volume":"10","author":"L Lione","year":"2021","unstructured":"Lione L, Salvatori E, Petrazzuolo A et al (2021) Antitumor efficacy of a neoantigen cancer vaccine delivered by electroporation is influenced by microbiota composition. Oncoimmunology 10:1898832. https:\/\/doi.org\/10.1080\/2162402X.2021.1898832","journal-title":"Oncoimmunology"},{"issue":"12","key":"107_CR71","doi-asserted-by":"publisher","first-page":"731798","DOI":"10.3389\/fphar.2021.731798","volume":"1","author":"J Liu","year":"2021","unstructured":"Liu J, Chen Z, Li Y, Zhao W, Wu J, Zhang Z (2021) PD-1\/PD-L1 checkpoint inhibitors in tumor immunotherapy. Front Pharmacol 1(12):731798. https:\/\/doi.org\/10.3389\/fphar.2021.731798","journal-title":"Front Pharmacol"},{"key":"107_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1186892","volume":"14","author":"XF Liu","year":"2023","unstructured":"Liu XF, Shao JH, Liao YT et al (2023) Regulation of short-chain fatty acids in the immune system. Front Immunol 14:1186892. https:\/\/doi.org\/10.3389\/fimmu.2023.1186892","journal-title":"Front Immunol"},{"key":"107_CR73","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/intimm\/dxaa079","volume":"33","author":"BC Lo","year":"2021","unstructured":"Lo BC, Chen GY, N\u00fa\u00f1ez G et al (2021) Gut microbiota and systemic immunity in health and disease. Int Immunol 33:197\u2013209. https:\/\/doi.org\/10.1093\/intimm\/dxaa079","journal-title":"Int Immunol"},{"key":"107_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41378-023-00640-x","volume":"10","author":"M Lucchetti","year":"2024","unstructured":"Lucchetti M, Werr G, Johansson S et al (2024) Integration of multiple flexible electrodes for real-time detection of barrier formation with spatial resolution in a gut-on-chip system. Microsyst Nanoeng 10:18. https:\/\/doi.org\/10.1038\/s41378-023-00640-x","journal-title":"Microsyst Nanoeng"},{"key":"107_CR75","doi-asserted-by":"publisher","unstructured":"Ma C, Han M, Heinrich B et al. Gut microbiome\u2013mediated bile acid metabolism regulates liver cancer via NKT cells. Science. 2018 May 25;360(6391):eaan5931. https:\/\/doi.org\/10.1126\/science.aan5931","DOI":"10.1126\/science.aan5931"},{"key":"107_CR76","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.immuni.2024.03.002","volume":"57","author":"M Ma","year":"2024","unstructured":"Ma M, Jiang W, Zhou R (2024) DAMPs and DAMP-sensing receptors in inflammation and diseases. Immunity 57:752\u2013771. https:\/\/doi.org\/10.1016\/j.immuni.2024.03.002","journal-title":"Immunity"},{"key":"107_CR77","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1126\/science.abc3421","volume":"369","author":"LF Mager","year":"2020","unstructured":"Mager LF, Burkhard R, Pett N et al (2020) Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science 369:1481\u20131489. https:\/\/doi.org\/10.1126\/science.abc3421","journal-title":"Science"},{"key":"107_CR78","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41568-022-00462-5","volume":"22","author":"SM Man","year":"2022","unstructured":"Man SM, Jenkins BJ (2022) Context-dependent functions of pattern recognition receptors in cancer. Nat Rev Cancer 22:397\u2013413. https:\/\/doi.org\/10.1038\/s41568-022-00462-5","journal-title":"Nat Rev Cancer"},{"key":"107_CR79","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003334","author":"J Mao","year":"2021","unstructured":"Mao J, Wang D, Long J et al (2021) Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-003334","journal-title":"J Immunother Cancer"},{"key":"107_CR80","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP et al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16:563\u2013580. https:\/\/doi.org\/10.1038\/s41571-019-0218-0","journal-title":"Nat Rev Clin Oncol"},{"key":"107_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21082668","volume":"21","author":"M Matija\u0161i\u0107","year":"2020","unstructured":"Matija\u0161i\u0107 M, Me\u0161trovi\u0107 T, \u010cip\u010di\u0107 Paljetak H et al (2020) Gut microbiota beyond bacteria\u2014mycobiome, virome, archaeome, and eukaryotic parasites in IBD. Int J Mol Sci 21:2668","journal-title":"Int J Mol Sci"},{"key":"107_CR82","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.aao3290","volume":"359","author":"V Matson","year":"2018","unstructured":"Matson V, Fessler J, Bao R et al (2018a) The commensal microbiome is associated with anti\u2013PD-1 efficacy in metastatic melanoma patients. Science 359:104\u2013108. https:\/\/doi.org\/10.1126\/science.aao3290","journal-title":"Science"},{"key":"107_CR83","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.aao3290","volume":"359","author":"V Matson","year":"2018","unstructured":"Matson V, Fessler J, Bao R et al (2018b) The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359:104\u2013108. https:\/\/doi.org\/10.1126\/science.aao3290","journal-title":"Science"},{"key":"107_CR84","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41591-022-01698-2","volume":"28","author":"JA McCulloch","year":"2022","unstructured":"McCulloch JA, Davar D, Rodrigues RR et al (2022) Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. Nat Med 28:545\u2013556. https:\/\/doi.org\/10.1038\/s41591-022-01698-2","journal-title":"Nat Med"},{"key":"107_CR85","doi-asserted-by":"publisher","first-page":"100069","DOI":"10.1016\/j.infpip.2020.100069","volume":"2","author":"B Merrick","year":"2020","unstructured":"Merrick B, Allen L, Masirah MZN et al (2020) Regulation, risk and safety of Faecal Microbiota Transplant. Infect Prev Pract 2:100069. https:\/\/doi.org\/10.1016\/j.infpip.2020.100069","journal-title":"Infect Prev Pract"},{"key":"107_CR86","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abn0704","volume":"7","author":"G Mirji","year":"2022","unstructured":"Mirji G, Worth A, Bhat SA et al (2022) The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer. Sci Immunol 7:eabn0704. https:\/\/doi.org\/10.1126\/sciimmunol.abn0704","journal-title":"Sci Immunol"},{"key":"107_CR87","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.chom.2021.08.001","volume":"29","author":"A Montalban-Arques","year":"2021","unstructured":"Montalban-Arques A, Katkeviciute E, Busenhart P et al (2021) Commensal Clostridiales strains mediate effective anti-cancer immune response against solid tumors. Cell Host Microbe 29:1573-1588.e1577. https:\/\/doi.org\/10.1016\/j.chom.2021.08.001","journal-title":"Cell Host Microbe"},{"key":"107_CR88","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/19490976.2015.1134082","volume":"7","author":"DJ Morrison","year":"2016","unstructured":"Morrison DJ, Preston T (2016) Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes 7:189\u2013200. https:\/\/doi.org\/10.1080\/19490976.2015.1134082","journal-title":"Gut Microbes"},{"key":"107_CR89","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13073-022-01037-7","volume":"14","author":"RC Newsome","year":"2022","unstructured":"Newsome RC, Gharaibeh RZ, Pierce CM et al (2022) Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort. Genome Medicine 14:35. https:\/\/doi.org\/10.1186\/s13073-022-01037-7","journal-title":"Genome Medicine"},{"key":"107_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12328-017-0813-5","volume":"11","author":"A Nishida","year":"2018","unstructured":"Nishida A, Inoue R, Inatomi O et al (2018) Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol 11:1\u201310. https:\/\/doi.org\/10.1007\/s12328-017-0813-5","journal-title":"Clin J Gastroenterol"},{"key":"107_CR91","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1017\/gmb.2025.10007","volume":"6","author":"S Pakroo","year":"2025","unstructured":"Pakroo S, Soltani S, Tarrah A et al (2025) The effect of dietary transition on infant microbiota composition and metabolic activity captured with the simulator of the human intestinal microbial ecosystem (SHIME). Gut Microbiome (Camb) 6:e9. https:\/\/doi.org\/10.1017\/gmb.2025.10007","journal-title":"Gut Microbiome (Camb)"},{"key":"107_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00862-w","volume":"13","author":"C Pan","year":"2020","unstructured":"Pan C, Liu H, Robins E et al (2020) Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. J Hematol Oncol 13:29. https:\/\/doi.org\/10.1186\/s13045-020-00862-w","journal-title":"J Hematol Oncol"},{"key":"107_CR93","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41435-021-00129-5","volume":"22","author":"RB Panwar","year":"2021","unstructured":"Panwar RB, Sequeira RP, Clarke TB (2021) Microbiota-mediated protection against antibiotic-resistant pathogens. Genes Immun 22:255\u2013267. https:\/\/doi.org\/10.1038\/s41435-021-00129-5","journal-title":"Genes Immun"},{"key":"107_CR94","doi-asserted-by":"publisher","DOI":"10.4110\/in.2026.26.e7","author":"U Park","year":"2026","unstructured":"Park U, Heo J-Y, Chun S-m et al (2026) Harnessing the gut microbiota to improve cancer immunotherapy: focus on lung cancer. Immune Netw. https:\/\/doi.org\/10.4110\/in.2026.26.e7","journal-title":"Immune Netw"},{"key":"107_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2022.100822","volume":"32","author":"LB Peiffer","year":"2022","unstructured":"Peiffer LB, White JR, Jones CB et al (2022) Composition of gastrointestinal microbiota in association with treatment response in individuals with metastatic castrate resistant prostate cancer progressing on enzalutamide and initiating treatment with anti-PD-1 (pembrolizumab). Neoplasia 32:100822. https:\/\/doi.org\/10.1016\/j.neo.2022.100822","journal-title":"Neoplasia"},{"key":"107_CR96","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1158\/2326-6066.Cir-19-1014","volume":"8","author":"Z Peng","year":"2020","unstructured":"Peng Z, Cheng S, Kou Y et al (2020) The gut microbiome is associated with clinical response to anti\u2013PD-1\/PD-L1 immunotherapy in gastrointestinal cancer. Cancer Immunol Res 8:1251\u20131261. https:\/\/doi.org\/10.1158\/2326-6066.Cir-19-1014","journal-title":"Cancer Immunol Res"},{"key":"107_CR97","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1126\/science.abf8403","volume":"374","author":"N Pernigoni","year":"2021","unstructured":"Pernigoni N, Zagato E, Calcinotto A et al (2021) Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. Science 374:216\u2013224. https:\/\/doi.org\/10.1126\/science.abf8403","journal-title":"Science"},{"key":"107_CR98","doi-asserted-by":"publisher","first-page":"6201","DOI":"10.1038\/s41467-021-26431-4","volume":"12","author":"LCD Pomatto-Watson","year":"2021","unstructured":"Pomatto-Watson LCD, Bodogai M, Bosompra O et al (2021) Daily caloric restriction limits tumor growth more effectively than caloric cycling regardless of dietary composition. Nat Commun 12:6201. https:\/\/doi.org\/10.1038\/s41467-021-26431-4","journal-title":"Nat Commun"},{"key":"107_CR99","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","volume":"21","author":"S Qin","year":"2020","unstructured":"Qin S, Ren Z, Meng Z et al (2020) Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol 21:571\u2013580. https:\/\/doi.org\/10.1016\/S1470-2045(20)30011-5","journal-title":"Lancet Oncol"},{"issue":"12","key":"107_CR100","doi-asserted-by":"publisher","first-page":"643255","DOI":"10.3389\/fimmu.2021.643255","volume":"13","author":"AL Reens","year":"2021","unstructured":"Reens AL, Cabral DJ, Liang X, Norton JE Jr, Therien AG, Hazuda DJ, Swaminathan G (2021) Immunomodulation by the commensal microbiome during immune-targeted interventions: focus on cancer immune checkpoint inhibitor therapy and vaccination. Front Immunol 13(12):643255. https:\/\/doi.org\/10.3389\/fimmu.2021.643255","journal-title":"Front Immunol"},{"key":"107_CR101","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1136\/gutjnl-2023-329614","volume":"73","author":"M Rehan","year":"2024","unstructured":"Rehan M, Al-Bahadly I, Thomas DG et al (2024) Smart capsules for sensing and sampling the gut: status, challenges and prospects. Gut 73:186\u2013202. https:\/\/doi.org\/10.1136\/gutjnl-2023-329614","journal-title":"Gut"},{"key":"107_CR102","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1158\/2159-8290.Cd-21-0425","volume":"11","author":"A Ribas","year":"2021","unstructured":"Ribas A, Medina T, Kirkwood JM et al (2021) Overcoming PD-1 blockade resistance with CpG-A toll-like receptor 9 agonist vidutolimod in patients with metastatic melanoma. Cancer Discov 11:2998\u20133007. https:\/\/doi.org\/10.1158\/2159-8290.Cd-21-0425","journal-title":"Cancer Discov"},{"key":"107_CR103","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","volume":"11","author":"C Robert","year":"2020","unstructured":"Robert C (2020) A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun 11:3801. https:\/\/doi.org\/10.1038\/s41467-020-17670-y","journal-title":"Nat Commun"},{"key":"107_CR104","doi-asserted-by":"publisher","DOI":"10.3402\/mehd.v26.26050","volume":"26","author":"JM Rodr\u00cdguez","year":"2015","unstructured":"Rodr\u00cdguez JM, Murphy K, Stanton C et al (2015) The composition of the gut microbiota throughout life, with an emphasis on early life. Microb Ecol Health Dis 26:26050. https:\/\/doi.org\/10.3402\/mehd.v26.26050","journal-title":"Microb Ecol Health Dis"},{"key":"107_CR105","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L et al (2018) Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors. Science 359:91\u201397. https:\/\/doi.org\/10.1126\/science.aan3706","journal-title":"Science"},{"issue":"12","key":"107_CR106","doi-asserted-by":"publisher","first-page":"670286","DOI":"10.3389\/fimmu.2021.670286","volume":"31","author":"ML Schubert","year":"2021","unstructured":"Schubert ML, Rohrbach R, Schmitt M, Stein-Thoeringer CK (2021) The potential role of the intestinal micromilieu and individual microbes in the immunobiology of chimeric antigen receptor t-cell therapy. Front Immunol 31(12):670286. https:\/\/doi.org\/10.3389\/fimmu.2021.670286","journal-title":"Front Immunol"},{"key":"107_CR107","doi-asserted-by":"publisher","first-page":"360","DOI":"10.5217\/ir.2020.00116","volume":"19","author":"K Sehgal","year":"2021","unstructured":"Sehgal K, Khanna S (2021) Gut microbiome and checkpoint inhibitor colitis. Intest Res 19:360\u2013364. https:\/\/doi.org\/10.5217\/ir.2020.00116","journal-title":"Intest Res"},{"key":"107_CR108","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA et al (2022) Immune checkpoint inhibitors in cancer therapy. Curr Oncol 29:3044\u20133060. https:\/\/doi.org\/10.3390\/curroncol29050247","journal-title":"Curr Oncol"},{"key":"107_CR109","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1136\/gutjnl-2020-323426","volume":"71","author":"W Si","year":"2022","unstructured":"Si W, Liang H, Bugno J et al (2022) Lactobacillus rhamnosus GG induces cGAS\/STING- dependent type I interferon and improves response to immune checkpoint blockade. Gut 71:521\u2013533. https:\/\/doi.org\/10.1136\/gutjnl-2020-323426","journal-title":"Gut"},{"key":"107_CR110","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1038\/s41591-022-01965-2","volume":"28","author":"RC Simpson","year":"2022","unstructured":"Simpson RC, Shanahan ER, Batten M et al (2022) Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome. Nat Med 28:2344\u20132352. https:\/\/doi.org\/10.1038\/s41591-022-01965-2","journal-title":"Nat Med"},{"key":"107_CR111","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1126\/science.aac4255","volume":"350","author":"A Sivan","year":"2015","unstructured":"Sivan A, Corrales L, Hubert N et al (2015) Commensal Bifidobacterium promotes antitumor immunity and facilitates anti\u2013PD-L1 efficacy. Science 350:1084\u20131089. https:\/\/doi.org\/10.1126\/science.aac4255","journal-title":"Science"},{"key":"107_CR112","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s41591-022-01702-9","volume":"28","author":"M Smith","year":"2022","unstructured":"Smith M, Dai A, Ghilardi G et al (2022) Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat Med 28:713\u2013723. https:\/\/doi.org\/10.1038\/s41591-022-01702-9","journal-title":"Nat Med"},{"issue":"13","key":"107_CR113","doi-asserted-by":"publisher","first-page":"781934","DOI":"10.3389\/fimmu.2022.781934","volume":"21","author":"B Song","year":"2022","unstructured":"Song B, Li P, Yan S, Liu Y, Gao M, Lv H, Lv Z, Guo Y (2022) Effects of dietary astragalus polysaccharide supplementation on the Th17\/Treg balance and the gut microbiota of broiler chickens challenged with necrotic enteritis. Front Immunol 21(13):781934. https:\/\/doi.org\/10.3389\/fimmu.2022.781934","journal-title":"Front Immunol"},{"key":"107_CR114","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrmicro.2016.17","volume":"14","author":"P Spanogiannopoulos","year":"2016","unstructured":"Spanogiannopoulos P, Bess EN, Carmody RN et al (2016) The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism. Nat Rev Microbiol 14:273\u2013287. https:\/\/doi.org\/10.1038\/nrmicro.2016.17","journal-title":"Nat Rev Microbiol"},{"key":"107_CR115","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1126\/science.aaz7015","volume":"374","author":"CN Spencer","year":"2021","unstructured":"Spencer CN, McQuade JL, Gopalakrishnan V et al (2021) Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science 374:1632\u20131640. https:\/\/doi.org\/10.1126\/science.aaz7015","journal-title":"Science"},{"issue":"8","key":"107_CR116","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.3389\/fimmu.2017.01353","volume":"30","author":"M Spiljar","year":"2017","unstructured":"Spiljar M, Merkler D, Trajkovski M (2017) The immune system bridges the gut microbiota with systemic energy homeostasis: focus on tlrs, mucosal barrier, and SCFAs. Front Immunol 30(8):1353. https:\/\/doi.org\/10.3389\/fimmu.2017.01353","journal-title":"Front Immunol"},{"key":"107_CR117","doi-asserted-by":"publisher","first-page":"2523815","DOI":"10.1080\/19490976.2025.2523815","volume":"17","author":"Y Tang","year":"2025","unstructured":"Tang Y, Fu A, Wang L et al (2025) Microbiota-dependent metabolites - New engine for T cell warriors. Gut Microbes 17:2523815. https:\/\/doi.org\/10.1080\/19490976.2025.2523815","journal-title":"Gut Microbes"},{"key":"107_CR118","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41586-019-0878-z","volume":"565","author":"T Tanoue","year":"2019","unstructured":"Tanoue T, Morita S, Plichta DR et al (2019) A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature 565:600\u2013605. https:\/\/doi.org\/10.1038\/s41586-019-0878-z","journal-title":"Nature"},{"key":"107_CR119","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1080\/10408398.2018.1555789","volume":"60","author":"J Tao","year":"2020","unstructured":"Tao J, Li S, Gan R-Y et al (2020) Targeting gut microbiota with dietary components on cancer: effects and potential mechanisms of action. Crit Rev Food Sci Nutr 60:1025\u20131037. https:\/\/doi.org\/10.1080\/10408398.2018.1555789","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"3","key":"107_CR120","doi-asserted-by":"publisher","first-page":"e004191","DOI":"10.1136\/jitc-2021-004191","volume":"10","author":"S Terrisse","year":"2022","unstructured":"Terrisse S, Goubet AG, Ueda K, Thomas AM, Quiniou V, Thelemaque C, Dunsmore G, Clave E, Gamat-Huber M, Yonekura S, Ferrere G (2022) Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer. J Immunother Cancer 10(3):e004191. https:\/\/doi.org\/10.1136\/jitc-2021-004191","journal-title":"J Immunother Cancer"},{"key":"107_CR121","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1016\/j.cmet.2024.10.019","volume":"36","author":"H Tong","year":"2024","unstructured":"Tong H, Jiang Z, Song L et al (2024) Dual impacts of serine\/glycine-free diet in enhancing antitumor immunity and promoting evasion via PD-L1 lactylation. Cell Metab 36:2493-2510.e2499. https:\/\/doi.org\/10.1016\/j.cmet.2024.10.019","journal-title":"Cell Metab"},{"key":"107_CR122","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1093\/nutrit\/nuw067","volume":"75","author":"CM van der Beek","year":"2017","unstructured":"van der Beek CM, Dejong CHC, Troost FJ et al (2017) Role of short-chain fatty acids in colonic inflammation, carcinogenesis, and mucosal protection and healing. Nutr Rev 75:286\u2013305. https:\/\/doi.org\/10.1093\/nutrit\/nuw067","journal-title":"Nutr Rev"},{"key":"107_CR123","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.aad1329","volume":"350","author":"M V\u00e9tizou","year":"2015","unstructured":"V\u00e9tizou M, Pitt JM, Daill\u00e8re R et al (2015) Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350:1079\u20131084. https:\/\/doi.org\/10.1126\/science.aad1329","journal-title":"Science"},{"key":"107_CR124","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1073\/pnas.1712901115","volume":"115","author":"F Wang","year":"2018","unstructured":"Wang F, Yin Q, Chen L et al (2018) Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade. Proc Natl Acad Sci U S A 115:157\u2013161. https:\/\/doi.org\/10.1073\/pnas.1712901115","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"107_CR125","doi-asserted-by":"publisher","first-page":"1096551","DOI":"10.3389\/fimmu.2022.1096551","volume":"16","author":"M Wang","year":"2023","unstructured":"Wang M, Zhang L, Chang W, Zhang Y (2023) The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomes. Front Immunol 16(13):1096551. https:\/\/doi.org\/10.3389\/fimmu.2022.1096551","journal-title":"Front Immunol"},{"key":"107_CR126","doi-asserted-by":"publisher","first-page":"4137","DOI":"10.1016\/j.cell.2021.06.019","volume":"184","author":"HC Wastyk","year":"2021","unstructured":"Wastyk HC, Fragiadakis GK, Perelman D et al (2021) Gut-microbiota-targeted diets modulate human immune status. Cell 184:4137-4153.e4114. https:\/\/doi.org\/10.1016\/j.cell.2021.06.019","journal-title":"Cell"},{"key":"107_CR127","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.tim.2019.09.005","volume":"28","author":"PI Watnick","year":"2020","unstructured":"Watnick PI, Jugder B-E (2020) Microbial control of intestinal homeostasis via enteroendocrine cell innate immune signaling. Trends Microbiol 28:141\u2013149. https:\/\/doi.org\/10.1016\/j.tim.2019.09.005","journal-title":"Trends Microbiol"},{"key":"107_CR128","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1002\/ijc.34118","volume":"151","author":"H Wu","year":"2022","unstructured":"Wu H, Zheng X, Pan T et al (2022a) Dynamic microbiome and metabolome analyses reveal the interaction between gut microbiota and anti-PD-1 based immunotherapy in hepatocellular carcinoma. Int J Cancer 151:1321\u20131334. https:\/\/doi.org\/10.1002\/ijc.34118","journal-title":"Int J Cancer"},{"key":"107_CR129","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1080\/10408398.2020.1828813","volume":"62","author":"J Wu","year":"2022","unstructured":"Wu J, Zhao Y, Wang X et al (2022b) Dietary nutrients shape gut microbes and intestinal mucosa via epigenetic modifications. Crit Rev Food Sci Nutr 62:783\u2013797. https:\/\/doi.org\/10.1080\/10408398.2020.1828813","journal-title":"Crit Rev Food Sci Nutr"},{"key":"107_CR130","doi-asserted-by":"publisher","first-page":"105230","DOI":"10.1016\/j.critrevonc.2026.105230","volume":"221","author":"Q-L Wu","year":"2026","unstructured":"Wu Q-L, Zhou Y-R, Chen Z-R et al (2026) Roles of the gut microbiota in cancer immunotherapy: Mechanistic foundations and therapeutic opportunities. Crit Rev Oncol Hematol 221:105230. https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105230","journal-title":"Crit Rev Oncol Hematol"},{"key":"107_CR131","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1038\/s41423-025-01326-2","volume":"22","author":"M Xie","year":"2025","unstructured":"Xie M, Li X, Lau HC-H et al (2025) The gut microbiota in cancer immunity and immunotherapy. Cell Mol Immunol 22:1012\u20131031. https:\/\/doi.org\/10.1038\/s41423-025-01326-2","journal-title":"Cell Mol Immunol"},{"issue":"15","key":"107_CR132","doi-asserted-by":"publisher","first-page":"1471273","DOI":"10.3389\/fimmu.2024.1471273","volume":"28","author":"J Yan","year":"2024","unstructured":"Yan J, Yang L, Ren Q, Zhu C, Du H, Wang Z, Qi Y, Xian X, Chen D (2024) Gut microbiota as a biomarker and modulator of anti-tumor immunotherapy outcomes. Front Immunol 28(15):1471273. https:\/\/doi.org\/10.3389\/fimmu.2024.1471273","journal-title":"Front Immunol"},{"key":"107_CR133","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1053\/j.gastro.2021.08.041","volume":"162","author":"J Yang","year":"2022","unstructured":"Yang J, Wei H, Zhou Y et al (2022) High-fat diet promotes colorectal tumorigenesis through modulating gut microbiota and metabolites. Gastroenterology 162:135-149.e132. https:\/\/doi.org\/10.1053\/j.gastro.2021.08.041","journal-title":"Gastroenterology"},{"key":"107_CR134","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13050957","volume":"13","author":"Y Yoon","year":"2021","unstructured":"Yoon Y, Kim G, Jeon B-N et al (2021) Bifidobacterium strain-specific enhances the efficacy of cancer therapeutics in tumor-bearing mice. Cancers (Basel) 13:957","journal-title":"Cancers (Basel)"},{"key":"107_CR135","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112514","volume":"13","author":"F Zhang","year":"2021","unstructured":"Zhang F, Ferrero M, Dong N et al (2021) Analysis of the gut microbiota: an emerging source of biomarkers for immune checkpoint blockade therapy in non-small cell lung cancer. Cancers (Basel) 13:2514","journal-title":"Cancers (Basel)"},{"key":"107_CR136","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2022.2046246","volume":"14","author":"S-L Zhang","year":"2022","unstructured":"Zhang S-L, Han B, Mao Y-Q et al (2022a) Lacticaseibacillus paracasei sh2020 induced antitumor immunity and synergized with anti-programmed cell death 1 to reduce tumor burden in mice. Gut Microbes 14:2046246. https:\/\/doi.org\/10.1080\/19490976.2022.2046246","journal-title":"Gut Microbes"},{"key":"107_CR137","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z (2020) The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol 17:807\u2013821. https:\/\/doi.org\/10.1038\/s41423-020-0488-6","journal-title":"Cell Mol Immunol"},{"key":"107_CR138","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14010073","volume":"14","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Kuo JC-T, Yao S et al (2022b) CpG oligodeoxynucleotides for anticancer monotherapy from preclinical stages to clinical trials. Pharmaceutics 14:73","journal-title":"Pharmaceutics"},{"key":"107_CR139","doi-asserted-by":"publisher","first-page":"10023","DOI":"10.1039\/D2FO01747D","volume":"13","author":"J Zhao","year":"2022","unstructured":"Zhao J, Wang Y, Wang J et al (2022) Lactobacillus kefiranofaciens ZW18 from kefir enhances the anti-tumor effect of anti-programmed cell death 1 (PD-1) immunotherapy by modulating the gut microbiota. Food Funct 13:10023\u201310033. https:\/\/doi.org\/10.1039\/D2FO01747D","journal-title":"Food Funct"},{"key":"107_CR140","doi-asserted-by":"publisher","unstructured":"Zhao MA, Chu J, Feng S, Guo C, Xue B, He K, Li L (2023) Immunological mechanisms of inflammatory diseases caused by gut microbiota dysbiosis: A review. Biomed Pharmacother 1(164):114985. https:\/\/doi.org\/10.1016\/j.biopha.2023.114985","DOI":"10.1016\/j.biopha.2023.114985"}],"container-title":["Saudi Pharmaceutical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44446-026-00107-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44446-026-00107-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44446-026-00107-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:03:05Z","timestamp":1788908585000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44446-026-00107-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":140,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["107"],"URL":"https:\/\/doi.org\/10.1007\/s44446-026-00107-w","relation":{},"ISSN":["1319-0164","2213-7475"],"issn-type":[{"value":"1319-0164","type":"print"},{"value":"2213-7475","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"21 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares none.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required for this review as it is based solely on previously published studies.","order":2,"name":"Ethics","label":"Ethical statement","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"52"}}